Dual functioning ionic liquids and salts thereof

US9278134B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9278134-B2
Application numberUS-200913142559-A
CountryUS
Kind codeB2
Filing dateDec 29, 2009
Priority dateDec 29, 2008
Publication dateMar 8, 2016
Grant dateMar 8, 2016

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Disclosed herein are ionic liquid compositions comprising active pharmaceutical, biological, and nutritional compounds, and methods of use. Further disclosed are compositions of matter including liquid ion pairs alone or in solution and their use; compositions of ionic liquids that are ‘solvated,’ for example, ‘hydrated’ and their uses.

First claim

Opening claim text (preview).

What is claimed is: 1. A method for preparing a bioactive co-ionic ionic liquid composition comprising: combining two pharmaceutical actives selected from single charged cations, cation precursors, and combinations thereof, represented as B 1 and B 2 , with one anion having a single negative charge, represented as A, or combining two pharmaceutical actives selected from single charged anions, anion precursors, and combinations thereof, represented as A 1 and A 2 , with one cation having a single positive charge, represented as B, thereby producing a co-ionic liquid [B 1 HB 2 ]A or B[A 1 HA 2 ], where H is hydrogen, that is liquid at a temperature at or below about 150° C., wherein B 1 and B 2 are selected from choline, lidocaine, tramadolium, caffeine, cetylpyridinium, ephedrinium, propantheline, acetaminophen derivative, procainamide, promethazine, and combinations thereof, and wherein A 1 and A 2 are selected from salicylate, ibuprofenate, lactate, camphorsulfonate, trans-cinnamate, docusate, niacinate, clofibrate, and combinations thereof. 2. The method of claim 1 wherein from about 75% to about 100% of the composition comprises an ion pair. 3. The method of claim 1 , wherein the cations and anions or the cation precursors and anion precursors are combined in the presence of one or more solvents, thereby producing a solvated ionic liquid; wherein at least a portion of the solvent provides direct solvation. 4. The method according to claim 1 , wherein combining two anions or anion precursors, represented as A 1 and A 2 , with one cation, represented as B, is by adding acid HA 2 to a non-protic ionic liquid having the formula BA 1 . 5. The method according to claim 1 , wherein combining two cations or cation precursors, represented as B 1 and B 2 , with one anion, represented as A, is by adding base B 2 to an ionic liquid having the formula [B 1 H]A. 6. The method according to claim 1 , wherein combining the two cation precursor with one anion or two anion precursor with one cation is accomplished by an acid-base neutralization reaction. 7. The method according to claim 1 , wherein the cation B comprises tetrabutylphosphonium and the anion A comprises salicylate and ibuprofenate, cinnamate, camphorsulfonate, lactate or thiosalicylate. 8. The method according to claim 1 , wherein the cation B is tetrabutylphosphonium and the anions A 1 and A 2 are ibuprofenate or niacinate. 9. The method according to claim 1 , wherein the cation B is cetylpyridinium and the anions A 1 and A 2 are salicylate and ibuprofenate, cinnamate, or clofibrate. 10. The method according to claim 1 , wherein the cation B is lidocaine and the anions A 1 and A 2 are salicylate and Ibuprofenate. 11. The method according to claim 1 , wherein the cation B is tramadolium and the anions A 1 and A 2 are salicylate and ibuprofenate. 12. The method according to claim 1 , wherein the cations B 1 and B 2 are ephedrinium and lidocaine and the anion A is ibuprofenate. 13. The method according to claim 1 , wherein the cations B 1 and B 2 are tramadolium and lidocaine and the anion A is salicylate or ibuprofenate. 14. The method according to claim 1 , wherein the cations B 1 and B 2 are promethazine and ephedrine and the anion A is docusate or salicylate.

Assignees

Inventors

Classifications

  • Human Necessities · mapped topic

  • A61K47/541Primary

    Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9278134B2 cover?
Disclosed herein are ionic liquid compositions comprising active pharmaceutical, biological, and nutritional compounds, and methods of use. Further disclosed are compositions of matter including liquid ion pairs alone or in solution and their use; compositions of ionic liquids that are ‘solvated,’ for example, ‘hydrated’ and their uses.
Who is the assignee on this patent?
Rogers Robin D, Daly Daniel T, Macfarlane Douglas, and 9 more
What technology area does this patent fall under?
Primary CPC classification A61K47/4803. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Mar 08 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).